<code id='425F13285C'></code><style id='425F13285C'></style>
    • <acronym id='425F13285C'></acronym>
      <center id='425F13285C'><center id='425F13285C'><tfoot id='425F13285C'></tfoot></center><abbr id='425F13285C'><dir id='425F13285C'><tfoot id='425F13285C'></tfoot><noframes id='425F13285C'>

    • <optgroup id='425F13285C'><strike id='425F13285C'><sup id='425F13285C'></sup></strike><code id='425F13285C'></code></optgroup>
        1. <b id='425F13285C'><label id='425F13285C'><select id='425F13285C'><dt id='425F13285C'><span id='425F13285C'></span></dt></select></label></b><u id='425F13285C'></u>
          <i id='425F13285C'><strike id='425F13285C'><tt id='425F13285C'><pre id='425F13285C'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:focus    Page View:18913

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In